Breaking News

ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement

For Lava’s Novel Bispecific Molecule.

 ProBioGen AG and Lava Therapeutics B.V. announced the closing of a cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.   Founded in 2016, Lava Therapeutics works on the development of antibody formats for the successful retrieval and activation of the body’s own immune system to effectively kill cancer cells in the tumor microenvironment. Under the agreement and using its CHO.RiGHT expression platform, including its recently launched Directed...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters